The in vitro antibacterial activity of gatifloxacin, a new quinolone antimicrobial agent
The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and...
Saved in:
Published in | Japanese Journal of Chemotherapy Vol. 47; no. Supplement2; pp. 3 - 11 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | Japanese |
Published |
Japanese Society of Chemotherapy
1999
公益社団法人 日本化学療法学会 |
Subjects | |
Online Access | Get full text |
ISSN | 1340-7007 1884-5886 |
DOI | 10.11250/chemotherapy1995.47.Supplement2_3 |
Cover
Abstract | The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp. The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum. The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition. |
---|---|
AbstractList | The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones.GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp.The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum.The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition.
新キノロン系抗菌薬gatifloxacin (GFLX) のin vitro抗菌力について他の新キノロン系抗菌薬との比較を行った。GFLXはグラム陽性菌, グラム陰性菌, 嫌気性菌およびMycobacterium spp. に対して幅広く強い抗菌力を示した。Staphylococcus aureus subsp. aureusおよびStreptococcus pneumoniaeを含む臨床分離のグラム陽性菌に対するGFLXの抗菌力はnorfloxacin (NFLX), ciprofloxacin (CPFX) およびlevofloxacin (LVFX) より優れ, tosufloxacin (TFLX) およびsparfloxacin (SPFX) と同等であった。腸内細菌科およびブドウ糖非 発酵桿菌を含む臨床分離のグラム陰性菌に対するGFLXの抗菌力はNFLX, SPFXおよびLVFXと同等で, CPFXおよびTFLXよりやや劣っていた。Haemophilus inflenzaeの臨床分離株に対するGFLXの抗菌力はNFLX, CPFX, SPFXおよびTFLXより優れ, LVFXと同等であった。臨床分離のMycoplasma pneumoniaeおよびUreaplasma urealyticum に対するGFLXの抗菌力は, CPFXより優れ, SPFXと同等であった。GFLXの抗菌力は, 培地の種類, 接種菌量, 培地のpH, ヒト血清および尿による影響を受けなかった。一方, Mg++の添加により抗菌力の低下が認められたが, これはCPFXと同程度であった。 The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones. GFLX showed a broad spectrum of potent antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, and Mycobacterium spp. The antibacterial activity of GFLX was superior to that of norfloxacin (NFLX), ciprofloxacin (CPFX), and levofloxacin (LVFX), and comparable to that of tosufloxacin (TFLX) and sparfloxacin (SPFX) against clinical isolates of Gram-positive bacteria, including Staphylococcus aureus subsp. aureus and Streptococcus pneumoniae. Against clinical isolates of Gram-negative bacteria, including the family Enterobacteriaceae and glucose-nonfermentative rods, GFLX possessed the same antibacterial activity as NFLX, SPFX, and LVFX, and only slightly lower activity than CPFX and TFLX. Against Haemophilus infiuenzae, the antibacterial activity of GFLX was superior to that of NFLX, CPFX, TFLX, and SPFX, and comparable to that of LVFX. GFLX showed higher antibacterial activity than CPFX and the same antibacterial activity as SPFX against clinical isolates of Mycoplasma pneumoniae and Ureaplasma urealyticum. The in vitro antibacterial activity of GFLX was not influenced by the type of medium, inoculum size, pH of medium, or addition of human serum or human urine. However, the activity of GFLX decreased in the presence of Mg++, similar to the decrease in activity of CPFX in the same condition. |
Author | Yasue, Tokutaro Oomori, Yasuo Yamamoto, Takao Hosaka, Masaki Fukuda, Hideyuki Tomizawa, Hiroshi Hori, Shizuko |
Author_FL | 安江 徳太郎 山本 隆雄 大森 康男 保坂 雅喜 福田 秀行 堀 閑子 富澤 寛 |
Author_FL_xml | – sequence: 1 fullname: 福田 秀行 – sequence: 2 fullname: 大森 康男 – sequence: 3 fullname: 山本 隆雄 – sequence: 4 fullname: 安江 徳太郎 – sequence: 5 fullname: 富澤 寛 – sequence: 6 fullname: 堀 閑子 – sequence: 7 fullname: 保坂 雅喜 |
Author_xml | – sequence: 1 fullname: Yamamoto, Takao organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Tomizawa, Hiroshi organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Fukuda, Hideyuki organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Hori, Shizuko organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Hosaka, Masaki organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Yasue, Tokutaro organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd – sequence: 1 fullname: Oomori, Yasuo organization: Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd |
BackLink | https://cir.nii.ac.jp/crid/1390282681266376832$$DView record in CiNii |
BookMark | eNpdUE1LAzEUDFLBWvsfcvAkbs13skcpfkHBgxU8GZI026bsZtdtqvbfG1oPpZf3Zh4zj2EuwSC20QNwg9EEY8LRnVv5pk0r35tuh8uST5icvG27rvaNj4loegaGWClWcKXEIGPKUCERkhdgvNkEixDGSFBcDsHHfOVhiPA7pL6FJqZgjUu-D6aGGYR838G2gkuTQlW3v8aFeAsNjP4Hfm1DbOucbe9rgutbu_ctc4orcF6ZeuPH_3sE3h8f5tPnYvb69DK9nxVrwnAqSs95hQWzwiPnkLBYWFlJ43mmBGGHnBTeEm6cQgvqpCq5Qo4tLHMUM0FH4PrwN4agc7g8MS0RUUQoTISgUihKsuzzIFtvUs6nuz40pt9p06fgaq9PK9VM6uNKTyg9Mppe-0j_AGCdgXY |
ContentType | Journal Article |
Copyright | Japanese Society of Chemotherapy |
Copyright_xml | – notice: Japanese Society of Chemotherapy |
DBID | RYH |
DOI | 10.11250/chemotherapy1995.47.Supplement2_3 |
DatabaseName | CiNii Complete |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | 新キノロン系抗菌薬gatifloxacinのin vitro抗菌力 |
DocumentTitle_FL | 新キノロン系抗菌薬gatifloxacinのin vitro抗菌力 |
EISSN | 1884-5886 |
EndPage | 11 |
ExternalDocumentID | 10008028874 article_chemotherapy1995_47_Supplement2_47_Supplement2_3_article_char_en |
GroupedDBID | 5GY ALMA_UNASSIGNED_HOLDINGS DIK JSF KQ8 P2P RJT RYH |
ID | FETCH-LOGICAL-j241t-9e55f164b6e0cc06b16b7f7ae50cc201c0c76eb25ac80d3c789580c4db4c31463 |
ISSN | 1340-7007 |
IngestDate | Fri Jun 27 00:41:44 EDT 2025 Wed Sep 03 06:28:59 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement2 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-j241t-9e55f164b6e0cc06b16b7f7ae50cc201c0c76eb25ac80d3c789580c4db4c31463 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/chemotherapy1995/47/Supplement2/47_Supplement2_3/_article/-char/en |
PageCount | 9 |
ParticipantIDs | nii_cinii_1390282681266376832 jstage_primary_article_chemotherapy1995_47_Supplement2_47_Supplement2_3_article_char_en |
PublicationCentury | 1900 |
PublicationDate | 1999 |
PublicationDateYYYYMMDD | 1999-01-01 |
PublicationDate_xml | – year: 1999 text: 1999 |
PublicationDecade | 1990 |
PublicationTitle | Japanese Journal of Chemotherapy |
PublicationTitleAlternate | Jpn. J. Chemother. |
PublicationTitle_FL | Jpn. J. Chemother 日化療会誌 日本化学療法学会雑誌 |
PublicationYear | 1999 |
Publisher | Japanese Society of Chemotherapy 公益社団法人 日本化学療法学会 |
Publisher_xml | – name: Japanese Society of Chemotherapy – name: 公益社団法人 日本化学療法学会 |
References | 5) Hosaka M, Kinoshita S, Toyama A, et al: Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 36: 293-301, 1995 7) 日本化学療法学会嫌気性菌MIC測定法検討委員会: 嫌気性菌の最小発育阻止濃度 (MIC) 測定法. Chemotherapy 27: 559-560, 1979 1) Hosaka M, Yasue T, Fukuda H, et al: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36: 2108-2117, 1992 9) Taylor-Robinson D, Martin-Bourgon C, Watanabe T, et al: Isolation of Tmycoplasmas from dogs and squirrel monkeys: Biological and serological comparison with those isolated from man and cattle. J Gen Microb 68: 97-107, 1971 10) 日本化学療法学会抗菌薬感受性測定法検討委員会: 微量液体希釈法によるMIC測定法 (微量液体希釈法)-日本化学療法学会標準法-. Chemotherapy 38: 103-105, 1990 11) Timmers K, Sternhlonz R: Ionization and divalent cation dissociation constants of nalidixic acid and oxolinic acid. Bioorganic Chem 9: 145-155, 1978 8) Osada Y, Ogawa H: Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother 23: 509-511, 1983 4) Ishida K, Kaku M, Irifune K, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae: J Antimicrob Chemother 34: 875-883, 1994 2) Tomioka H, Saito H, Sato K: Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 37: 1259-1263, 1993 6) 日本化学療法学会: 最小発育阻止濃度 (MIC) 測定法再改訂について. Chemotherapy 29: 76-79, 1981 3) Wakabayashi E, Mitsuhashi S: In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 38: 594-601, 1994 |
References_xml | – reference: 4) Ishida K, Kaku M, Irifune K, et al: In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae: J Antimicrob Chemother 34: 875-883, 1994 – reference: 5) Hosaka M, Kinoshita S, Toyama A, et al: Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemother 36: 293-301, 1995 – reference: 9) Taylor-Robinson D, Martin-Bourgon C, Watanabe T, et al: Isolation of Tmycoplasmas from dogs and squirrel monkeys: Biological and serological comparison with those isolated from man and cattle. J Gen Microb 68: 97-107, 1971 – reference: 3) Wakabayashi E, Mitsuhashi S: In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 38: 594-601, 1994 – reference: 6) 日本化学療法学会: 最小発育阻止濃度 (MIC) 測定法再改訂について. Chemotherapy 29: 76-79, 1981 – reference: 11) Timmers K, Sternhlonz R: Ionization and divalent cation dissociation constants of nalidixic acid and oxolinic acid. Bioorganic Chem 9: 145-155, 1978 – reference: 7) 日本化学療法学会嫌気性菌MIC測定法検討委員会: 嫌気性菌の最小発育阻止濃度 (MIC) 測定法. Chemotherapy 27: 559-560, 1979 – reference: 10) 日本化学療法学会抗菌薬感受性測定法検討委員会: 微量液体希釈法によるMIC測定法 (微量液体希釈法)-日本化学療法学会標準法-. Chemotherapy 38: 103-105, 1990 – reference: 1) Hosaka M, Yasue T, Fukuda H, et al: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother 36: 2108-2117, 1992 – reference: 8) Osada Y, Ogawa H: Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother 23: 509-511, 1983 – reference: 2) Tomioka H, Saito H, Sato K: Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 37: 1259-1263, 1993 |
SSID | ssib001106319 ssib050995465 ssib000940262 ssib001168255 ssib038076210 ssib002822060 ssib002670600 ssib058493824 ssj0003212010 |
Score | 1.4489055 |
Snippet | The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new quinolones.... The in vitro antibacterial activity of gatifloxacin (GFLX), a new fluoro-methoxy-quinolone agent, was studied and compared with that of other new... |
SourceID | nii jstage |
SourceType | Publisher |
StartPage | 3 |
SubjectTerms | gatifloxacin in vitro抗菌力 新キノロン系抗菌薬 |
Title | The in vitro antibacterial activity of gatifloxacin, a new quinolone antimicrobial agent |
URI | https://www.jstage.jst.go.jp/article/chemotherapy1995/47/Supplement2/47_Supplement2_3/_article/-char/en https://cir.nii.ac.jp/crid/1390282681266376832 |
Volume | 47 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Japanese Journal of Chemotherapy, 1999/09/27, Vol.47(Supplement2), pp.3-11 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW6ISFeEAgQA4b8wBMhxY2dr0cETAUET50oT5HjOigtTaAkCPg5_FKO4yT1xqQB1RQ1rpwlvifX5175HhPyiMlCKM2YHyiTrUqD2M8LvFeFZAgGtMa7boqT376L5qfi9TJcTia_nFVLbZNP1c8L60r-x6pog11Nlew_WHa8KBrwHfbFERbG8a9tXFbet7LZ1R6GqMyt9rKp_1f9thAgg0ZEo_hUf5fKCgZIs4-496UtTU690l3PbdkpMpmeH4e1MANnxXxq9qn0HPJqdAb62q0xJ3_SbtqV9OblSv9oN-WYvq239a70PsivbT36GLmV6F97C7mRTisw4C3qTdvIXb3PRxgNg_0sMdzNsN70oruxXpabZYzMbnc71bYtSYQfJr0udu-arRhnD8Fum9MuZxo4Hpc7U7d1239OCqB5MKVy7sUUpk9FjAlqvGbG91PiuFBxZouR4YnFAbkSxPHMLBt98eqNQ1ERgTuSi6BTEXcl8mYRgnCHkkZGr8ihXGBobB-iGv3_KNhTMvC51OxXP54nIuVJX9Fj2AYH92BWdGMY1avk8fDYTy99aDCvNeIQIzBxUJWlQ64WN8j1Hlj0mYX4TTJZy1tkCXjTsqIdvOkZeNMB3rQuqAvvJ1RSgJuO4KZnwE07cN8mpycvF8_nfr8RiL8GwWz8VIdhgbg-jzRTikX5LMrjIpY6xCmeXjEVRzoPQqkStuIqTtIwYUqscqE4qAC_Qw4r_Mu7hIoC4WSoUy3w4ZJL_OGioVAzofM4PyLv7XBkn63aS9a_3dn5kcxEnDmQPH_KnY5yB291RI4xvhmGAkfEXcbyRvwPlB8hPw_uXfL7fXLNSoaY9N8DctjsWn0MQtzkDztE_gbt_bRS |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+in+vitro+antibacterial+activity+of+gatifloxacin%2C+a+new+quinolone+antimicrobial+agent&rft.jtitle=Japanese+Journal+of+Chemotherapy&rft.au=Fukuda+Hideyuki&rft.au=Oomori+Yasuo&rft.au=Yamamoto+Takao&rft.au=Yasue+Tokutaro&rft.date=1999&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=1340-7007&rft.eissn=1884-5886&rft.volume=47&rft.issue=Supplement2&rft.spage=3&rft.epage=11&rft_id=info:doi/10.11250%2Fchemotherapy1995.47.supplement2_3&rft.externalDocID=10008028874 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-7007&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-7007&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-7007&client=summon |